FIG. 6.
In vivo activity of anti-CD19 CIR+ CTLs. Twenty-four NOD/SCID mice injected with 3 × 106 luciferase (ffLuc)-expressing Daudi cells, and developed exponentially growing tumors by day 3 after injection were imaged and divided into three groups: treated with RPMI medium (1), mock transfected (2), or anti-CD19 CIR-transfected (3) CTLs. Groups received injections of 5 × 106 CTLs on days 3, 6, and 9. The mice were imaged on days 3, 6, 9, 12, and 15. (A) Pseudocolor image representing light intensity and anatomic localization of the ffLuc– Daudi cells in representative mice. (B) Longitudinal monitoring of the bioluminescent signals of ffLuc+ Daudi cells injected into 3 groups of 24 NOD/SCID mice. Data are presented as geometric means of total photon flux normalized for exposure time, surface area, and initial signal for each group of mice; error bars represent the geometric SD.